In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome

DI PIETRO, MARIANA; PASCUALI, NATALIA; SCOTTI, LEOPOLDINA; IRUSTA, GRISELDA; BAS, DIANA; MAY, MARÍA; TESONE, MARTA; ABRAMOVICH, DALHIA; PARBORELL, FERNANDA

MOLECULAR HUMAN REPRODUCTION.

OXFORD UNIV PRESS

Año: 2017 p. 1 - 11

1360-9947

STUDY QUESTION: Can the bioactive lipid sphingosine-1 phosphate (S1P) act as an endothelial barrier-enhancing molecule and, in turn, restore the vascular integrity and homeostasis in a rat model of ovarian hyperstimulation syndrome (OHSS).STUDY ANSWER: In vivo administration of S1P may prevent the early onset of OHSS and decrease its severity.WHAT IS KNOWN ALREADY: Although advances in the prediction and treatment of OHSS have been made, complete prevention has not been possible yet. S1P in follicular fluid from women at risk of developing OHSS are lower in comparison from women who are not at such risk and administration of S1P in an OHSS rat model decreases ovarian capillary permeability.STUDY DESIGN SIZE, DURATION: We used an animal model that develops OHSS in immature Sprague-Dawley rats. The rats were randomly divided into three groups: the control group, which was injected with 10 IU of pregnant mare's serum gonadotropin (PMSG), and 10 IU of human chorionic gonadotropin (hCG) 48 h later; the OHSS group, which was injected with excessive doses of PMSG (50 IU/day) for 4 consecutive days, followed by hCG; and the OHSS + S1P group, which was injected with the same doses of PMSG and hCG as the OHSS group and then treated with 5 μl S1P (1 mM) under the bursa of both ovaries, whereas the other groups of animals received the S1P vehicle.PARTICIPANTS /MATERIALS, SETTING, METHODS: Rats were killed by decapitation 48 h after the hCG injection for ovary, endometrium and blood collection. The ovaries were weighed and then used for subsequent assays, while the serum was used for hormone assays. One of the ovaries from each rat (n = 6) was used for Western immunoblot and the other for immunohistochemical analysis. Statistical comparisons between groups were carried out.MAIN RESULTS AND THE ROLE OF CHANCE: S1P administration reduced the ovarian weight (p < 0.05), and decreased the concentration of serum progesterone in the OHSS group compared to the OHSS group without treatment (p < 0.001). The percentage of antral follicles in the OHSS group was lower than that in the control group. S1P increased the percentage of antral follicles (p < 0.05) and decreased the percentage of corpora lutea (p < 0.01) and cystic structures in the OHSS group (p < 0.05). S1P had no effect on the expression levels of the enzymes 3β-hydroxysteroid dehydrogenase (3βHSD) or cholesterol side-chain cleavage enzyme (P450scc), but reduced the levels of steroidogenic acute regulatory protein (StAR) in OHSS rat ovaries. (p < 0.05). S1P decreased the endothelial (p < 0.05) and periendothelial (p < 0.01) cell area in OHSS rat ovaries. S1P restored the levels of N-cadherin and VE-cadherin proteins to control values. Furthermore, S1P enhanced the levels of claudin-5, occludin (p < 0.05) and sphingosine-1-phosphate receptor 1 (S1PR1) in OHSS (p < 0.01). In addition, no histological differences were found in endometrium between OHSS and S1P-treated OHSS animals.LIMITATIONS REASONS FOR CAUTION: The results of this study were generated from an in vivo OHSS experimental model, which has been used by several authors and our group due to the similarity between the rat and human angiogenic systems. Further studies in patients will be needed to evaluate the effects of S1P in the pathogenesis of OHSS.WIDER IMPLICATIONS OF THE FINDINGS: These findings concern the pathophysiological importance of S1P in OHSS. More studies on the regulation of endothelial cell barrier function by S1P in reproductive pathological processes and its therapeutic application are required.